Understanding the Risk Factors for one of the Deadliest Cancers in the World Ft. Thomas F. Nealon III, National Board Chair and Chief Executive Officer, American Liver Foundation (ALF) and Ghassan Abou-Alfa, MD, Medical Oncologist and Liver Disease Specialist, Memorial Sloan Kettering Cancer Center in New York City Business, Life, and Coffee Powered by Jumpstart:HR, LLC (www.jumpstart-hr.com) Join the conversation on social media: Twitter: @BizLifeCoffee | @JoeyVPriceHR Instagram: @BusinessLifeAndCoffee | @JoeyVPriceHR
About This Episode:
A cure for Hepatitis C. Liver transplants becoming more commonplace. New therapies against liver cancer. During the 40 year history of the American Liver Foundation great progress has been made.
Unfortunately, liver cancer is one of the few cancers on the rise, with 40,000 new cases expected to be diagnosed this year. According to the ALF, being properly screened, avoiding risky behaviors and understanding risks associated with liver cancer, like chronic viral hepatitis, heavy alcohol abuse, obesity, type 2 diabetes and anabolic steroid use are among the most important steps a person can take.
About Ghassan K. Abou-Alfa, MD
Dr. Ghassan K. Abou-Alfa is an appointed physician at Memorial Sloan Kettering Cancer Center and associate professor of the Weill Cornell Medical College in New York. Dr. Abou-Alfa specializes in the treatment of gastrointestinal malignancies. He received his medical degree from the American University of Beirut, Lebanon, and completed his post-doctoral training at Yale University School of Medicine field. Dr. Abou-Alfa serves as the chair of the National Cancer Institute (NCI) Task Force for Hepatobiliary Cancers and the chair of the AIDS Malignancy Consortium (AMC) Non-AIDS Defining Malignancies (NADC) Liver/GI Task Force. He also co-chairs the hepatobiliary group of the Alliance cooperative group, and is a cadre member of both the gastrointestinal cancers and pharmacogenomics and population pharmacology committees. Dr Abou-Alfa who has lectured worldwide on the subject of cholangiocarcinoma, biliary cancers and hepatocellular carcinoma, is also a strong advocate for raising awareness and support for improving the outcome of patients with this disease, and enhancing oncologic education worldwide.
About Tom Nealon
Thomas F. Nealon III, National Board Chair and CEO of the American Liver Foundation. Mr. Nealon joined the ALF Board in 2009 and was elected National Board Chair in 2012. Under his direction, the American Liver Foundation has become the country's leading resource for patients and families living with liver disease, and a trusted voice for liverhealth, disease prevention, research and advocacy. He has helped further ALF's mission to facilitate, advocate and promote education, support and research for the prevention, treatment and cure of liver disease.Mr. Nealon is a graduate of Georgetown University and the Georgetown University Law Center.
The American Liver Foundation
The American Liver Foundation reaches more than two million people a year with timely and trusted information, education and support services through 16 regional divisions, the National toll-free hotline and an active online presence.
Comments will be approved before showing up.